In the first three quarters, Qizheng Tibetan Medicine’s operating revenue grew by nearly 20%, with a growth rate of nearly 30% in the third quarter.

Release time:

2022-10-28 16:42

On the evening of October 27, Qizheng Tibetan Medicine released its third-quarter report. For the first three quarters of the year, the company’s operating revenue reached 1.416 billion yuan, an increase of 19.08% year-on-year; net profit attributable to shareholders of the listed company was 360 million yuan, down 44.46% year-on-year; and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 373 million yuan, up 18.77% year-on-year. In the third quarter alone, the company achieved operating revenue of 519 million yuan, representing a year-on-year increase of 28.89%. Excluding the impact of non-recurring items, the company’s core business continued to demonstrate steady growth.

Qizheng Tibetan Medicine is a leading Chinese enterprise in the Tibetan medicine industry, primarily engaged in the research and development, production, and sales of innovative Tibetan medicines. It boasts 25 exclusive product varieties and 141 approved drug registration numbers. Its product portfolio covers areas including the musculoskeletal system, nervous system, digestive system, cardiovascular and cerebrovascular system, respiratory system, urinary system, gynecology, dermatology, and pediatrics.

Reporting media: Shanghai Securities Journal – China Securities Net

Report link: https://ggjd.cnstock.com/company/scp_ggjd/tjd_bbdj/202210/4972656.htm

The “Gansu Prescription,” a Tibetan medicine formula for preventing and treating epidemics, has proven effective against the epidemic.

In the first half of the year, Qizheng Tibetan Medicine’s revenue increased by 14.07% year-on-year, and its net profit excluding non-recurring items rose by 4.11% year-on-year.